Antibody-Drug Conjugates in Solid Tumors
نویسندگان
چکیده
Solid tumors account for approximately 90% of all types cancer. For many tumor types, the availability effective treatment options is limited and new targeted approaches that offer potential long-term survival are warranted. Antibody-drug conjugates (ADCs) a class drugs have emerged as promising therapeutic option shown significant clinical benefit in selected malignancies. ADCs highly drugs, comprising antigen-specific monoclonal antibodies conjugated to cytotoxic agents via stable chemical linker. The binding antibody target antigen leads internalization antibody-antigen complex through receptor-mediated endocytosis, followed by release cytotoxin during lysosomal processing. Three ADCs, trastuzumab emtansine, deruxtecan sacituzumab govitecan, now available Switzerland patients with early, locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer triple-negative cancer, respectively. In addition, enfortumab vedotin was recently approved Swissmedic adult previously treated urothelial Despite clear currently they some limitations, including dose-limiting toxicities poor penetration. However, while promise chemotherapeutic agent less toxicity has yet be fully realized solid tumors, more than 80 being evaluated active trials. purpose this article provide reader an up-to-date overview current landscape tumors.
منابع مشابه
Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
Attaching a cytotoxic "payload" to an antibody to form an antibody-drug conjugate (ADC) provides a mechanism for selective delivery of the cytotoxic agent to cancer cells via the specific binding of the antibody to cancer-selective cell surface molecules. The first ADC to receive marketing authorization was gemtuzumab ozogamicin, which comprises an anti-CD33 antibody conjugated to a highly pote...
متن کاملEvaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates
Background: Reduction/alkylation is one of the leading strategies for the development of antibody drug conjugates (ADCs). Precise control of the reduction process would not only yield a defined number of free thiols per antibody but also result in development of more homogenous conjugates. Methods: In the present study, we investigated the effect of various dithiothreitol (DTT) concentrations, ...
متن کاملMALDI-MS: a Rapid and Reliable Method for Drug-to-Antibody Ratio Determination of Antibody-Drug Conjugates
Background: It is believed that the loading value of anticancer drug conjugated to the monoclonal antibody, called drug-to-antibody ratio (DAR), is the main quality feature of antibody-drug conjugates. Methods: In this study, matrix assisted laser desorption/ionization mass spectrometry was used to determine the average molecular weight of trastuzumab and its three conjugated forms. The differe...
متن کاملAntibody Drug Conjugates for Cancer Therapy
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Healthbook TIMES
سال: 2022
ISSN: ['2673-2106', '2673-2092']
DOI: https://doi.org/10.36000/hbt.oh.2022.11.062